<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213146</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT010</org_study_id>
    <nct_id>NCT02213146</nct_id>
  </id_info>
  <brief_title>A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of BioChaperone to already marketed prandial human insulin preparations may
      accelerate the onset and shorten the duration of action due to facilitation of the insulin
      absorption after subcutaneous injection.

      The aim of the trial is to assess the efficacy and safety of BioChaperone human insulin in
      subjects with type 1 diabetes under a dose of 0.2 U/kg.

      This trial is a single center, randomised, double-blinded, three treatment, three-period
      cross-over, 10-hour euglycaemic clamp trial in subject with type 1 diabetes mellitus. Each
      subject will be randomly allocated to a single dose of BioChaperone human insulin 0.2 U/kg, a
      single dose of Huminsulin® Normal 0.2 U/kg and a single dose of Humalog® 0.2 U/kg on 3
      separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUCins(0-1h))</measure>
    <time_frame>1 hour</time_frame>
    <description>Area under the human insulin serum concentration - time curve from t=0 to 1 hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Early t0.5max ins/lisp</measure>
    <time_frame>up to 10 hours post administration</time_frame>
    <description>Time to first observed half maximum serum human insulin / insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 10 hours</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the glucose infusion rate - time curve from t=0 to 10 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Early t0.5 Glucose Infusion Rate max (GIRmax)</measure>
    <time_frame>10 hours</time_frame>
    <description>Time to first observed half maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: GIRmax - Maximum glucose infusion rate</measure>
    <time_frame>10 hours</time_frame>
    <description>Maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUCins/lisp(0-10h): Area under the human insulin / insulin lispro serum concentration</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the human insulin / insulin lispro serum concentration - Time curve from t=0 to 10 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax(ins/lisp) - Time to maximum observed serum human insulin concentration and insulin lispro concentration</measure>
    <time_frame>10 hours</time_frame>
    <description>Time to maximum observed serum human insulin concentration and insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax(ins/lisp)</measure>
    <time_frame>up to 10 hours</time_frame>
    <description>Maximum observed human insulin / insulin lispro serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours</measure>
    <time_frame>2 hours post administration</time_frame>
    <description>Area under the glucose infusion rate - time curve from t=0 to 2 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>BioChaperone human insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone Human Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Huminsulin® Normal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone human insulin</intervention_name>
    <description>Single dose of 0.2 U/kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone human insulin</arm_group_label>
    <arm_group_label>Human insulin</arm_group_label>
    <arm_group_label>Insulin lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huminsulin® Normal</intervention_name>
    <description>Single dose of 0.2 U/kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone human insulin</arm_group_label>
    <arm_group_label>Human insulin</arm_group_label>
    <arm_group_label>Insulin lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Single dose of 0.2 U/kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone human insulin</arm_group_label>
    <arm_group_label>Human insulin</arm_group_label>
    <arm_group_label>Insulin lispro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject with type 1 diabetes for at least 12 months

          -  Treated with multiple daily insulin injections or insulin pump (CSII) for at least 12
             months

          -  Body mass index: 18.5-28.0 kg BW·m-2

          -  HbA1c: ≤ 9.0%

        Exclusion Criteria:

          -  Diabetes mellitus type 2

          -  Receipt of any investigational product within 3 months prior to first dosing of
             investigational product in this trial

          -  Clinically significant abnormalities as judged by the Investigator

          -  Any systemic treatment with drugs known to interfere with glucose metabolism

          -  History of alcoholism or drug/chemical abuse as per Investigator's judgement

          -  Use of any tobacco or nicotine-contained product within one year prior to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>August 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

